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Effect of Low-Dose Perindopril/Indapamide on
Albuminuria in Diabetes
Preterax in Albuminuria Regression: PREMIER
Carl Erik Mogensen, Giancarlo Viberti, Serge Halimi, Eberhard Ritz, Luis Ruilope, György Jermendy,
Jiri Widimsky, Pinchas Sareli, Jan Taton, Juan Rull, Gürbüz Erdogan, Pieter W. De Leeuw,
Arthur Ribeiro, Ramiro Sanchez, Rachid Mechmeche, John Nolan, Jana Sirotiakova, Ahmed Hamani,
André Scheen, Bernhard Hess, Anton Luger, Stephen M. Thomas
Abstract—Microalbuminuria in diabetes is a risk factor for early death and an indicator for aggressive blood pressure (BP)
lowering. We compared a combination of 2 mg perindopril/0.625 mg indapamide with enalapril monotherapy on
albumin excretion rate (AER) in patients with type 2 diabetes, albuminuria, and hypertension in a 12-month,
randomized, double-blind, parallel-group international multicenter study. Four hundred eighty-one patients with type 2
diabetes and hypertension (systolic BP 140 mm Hg, 180 mm Hg, diastolic BP 110 mm Hg) were randomly
assigned (age 599 years, 77% previously treated for hypertension). Results from 457 patients (intention-to-treat
analysis) were available. After a 4-week placebo period, patients with albuminuria 20 and 500 g/min were
randomly assigned to a combination of 2 mg perindopril/0.625 mg indapamide or to 10 mg daily enalapril. After week
12, doses were adjusted on the basis of BP to a maximum of 8 mg perindopril/2.5 mg indapamide or 40 mg enalapril.
The main outcome measures were overnight AER and supine BP. Both treatments reduced BP. Perindopril/indapamide
treatment resulted in a statistically significant higher fall in both BP (3.0 [95% CI 5.6, 0.4], P0.012; systolic BP
1.5 [95% CI 3.0, 0.1] diastolic BP P0.019) and AER 42% (95% CI 50%, 33%) versus 27% (95% CI
37%, 16%) with enalapril. The greater AER reduction remained significant after adjustment for mean BP. Adverse
events were similar in the 2 groups. Thus, first-line treatment with low-dose combination perindopril/indapamide
induces a greater decrease in albuminuria than enalapril, partially independent of BP reduction. A BP-independent effect
of the combination may increase renal protection. (Hypertension. 2003;41:1063-1071.)
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Increased urinary albumin excretion is a major prognosticfactor both for progressive diabetic renal disease1,2 and
increased cardiovascular morbidity and mortality rates in
both type 1 and type 2 diabetes.3–5 Albuminuria in type 2
diabetes is associated with cardiovascular risk factors such as
raised blood pressure (BP), dyslipidemia, and endothelial
activation.4,6 Furthermore, regression of urinary albumin
excretion is associated with a better renal and cardiovascular
prognosis.7,8
Large multicenter trials have confirmed the benefits of
“tighter” BP control in type 2 diabetes9 and of the benefits of
inhibitors of the renin-angiotensin system (RAS), particularly
in patients with increased urinary albumin excretion.10,11
Treatment strategies vary and are often based on initial
monotherapy with high doses of single agents. Tight BP
control is, however, difficult to achieve in this group of
patients, and combination therapy is usually required.9 There
is, however, at present very little data to guide the most
appropriate combinations of therapy in patients with type 2
diabetes.
The combination of a diuretic and RAS inhibitor is
potentially advantageous. First, the RAS inhibitor offsets the
diuretic-induced increase in plasma renin activity, whereas
the diuretic-induced salt loss potentiates the effect of the RAS
inhibitor, an effect magnified by a reduced salt intake.12 The
use of this combination is particularly relevant in diabetes as
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the result of the specific renoprotective effects of ACE
inhibitors and the extra potential for sodium retention.12
The use of a low-dose combination of perindopril (a
long-acting ACE inhibitor) and indapamide (a non–thiazide
chlorosulfamoyl diuretic) as first-line treatment in hyperten-
sion gives greater BP normalization rates in comparison with
angiotensin II antagonists13 and a larger BP decrease than
atenolol.14
In salt-sensitive Dahl rats loaded with sodium, a model
with low plasma renin activity, the combination of perindo-
pril/indapamide for 8 weeks lowered proteinuria and reduced
glomerular lesions more than monotherapy with either agent
despite little systemic antihypertensive effect, suggesting a
BP-independent renoprotective effect.15
This study in patients with type 2 diabetes, hypertension,
and albuminuria therefore compared the combination of
low-dose perindopril/indapamide with monotherapy with
enalapril—an ACE inhibitor of proven efficacy8,16—to deter-
mine the most effective treatment strategy in terms of
albuminuria and BP lowering.
Methods
This study is described according to the CONSORT guidelines.17
Objective
The objective of the study was to compare low-dose 2 mg perindo-
pril/0.625 mg indapamide versus enalapril for 52 weeks on urinary
albumin excretion rate (AER) in patients with type 2 diabetes with
hypertension and albuminuria.
Design
The study was designed as a 12-month, randomized, controlled,
double-blind, 2–parallel group study conducted in 104 centers in 20
countries.
Patients
Patients between the ages of 40 and 75 years with type 2 diabe-
tes,18,19 hypertension defined as supine systolic BP (SBP)
140 mm Hg 180 mm Hg and supine diastolic BP (DBP)
110 mm Hg, and AER (20 g/min 500 g/min in at least 2 of
3 assays).
Patients with HbA1c 9% within the 3 months before the study,
with presumed nondiabetic kidney disease, serum creatinine 140
mol/L, known contraindications to ACE inhibitor therapy, or
indapamide or other severe disease were excluded. Nonstudy anti-
hypertensive drugs were not permitted.
Methods
The design is summarized in Figure 1. After an open 4-week
prerandomization run-in period of receiving placebo once daily,
patients were randomly assigned in a double-blind manner to
once-a-day therapy with either 2 mg perindopril/0.625 mg indapam-
ide or monotherapy with 10 mg enalapril.
Dose adjustment based on BP and/or BP response was permitted
after week 12, with doubling of the dosage in 2 steps at 12-week
intervals: W12, W24, or W36 in patients whose SBP remained
140 mm Hg and/or DBP 90 mm Hg. The adjustment was in
double-blind steps: 4 mg perindopril/ 1.25 mg indapamide or 20 mg
enalapril, then 8 mg perindopril/2.5 mg indapamide or 40 mg
enalapril. The choice of antidiabetic treatment was left to the
investigator.
After random assignment, the patients were seen on 7 occasions
over the next 52 weeks.
AER was determined at each visit from a timed overnight urine
collection,20 and infection was excluded by dipstick. Three AER and
urinary albumin/creatinine ratio21 (ACR) evaluations were per-
formed at baseline.21
BP was measured at rest after 10 minutes in the supine position
and after 1 and 3 minutes in the standing position with a mercury
sphygmomanometer in the morning at each visit at trough drug
levels. The mean of 3 measurements in the supine position was
taken.
HbA1c was determined by high-performance liquid chromatogra-
phy. Cardiovascular adverse events were defined according to the
International Classification of Disease (CD9–1975 revision, code
390–448, 7981, instantaneous death), and serious adverse events
were predefined as those that were fatal or required prolonged
hospitalization.
The primary outcome was the change in the AER (g/min) after
1 year. Secondary outcome criteria were ACR, supine BP, and BP
response defined as a reduction in SBP 140 mm Hg and DBP
90 mm Hg and/or reduction of SBP 20 mm Hg and/or reduction
of DBP 10 mm Hg.
Ethics
The study was performed in accordance with the Declaration of
Helsinki.22 Ethics committee approval was obtained for each center,
and written informed consent was obtained from all patients.
Statistical Analysis
Given the proven efficacy of ACE inhibitor therapy,23 the sample
size was calculated to allow assessment of the noninferiority of the
Figure 1. Study design. Per indicates perin-
dopril; Ind, indapamide.
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combination of perindopril/indapamide versus enalapril. This was
determined by using an 2.5%,24 with an assumed limit of
noninferiority at the final visit being a clinically significant differ-
ence in AER (35% of the value in the enalapril group).25 The
sample size was calculated to be 200 patients per group.26 AER and
ACR were logarithmically transformed and are presented as the
geometric means with their 95% confidence intervals.
All analyses were adjusted for the country of treatment with the
baseline value as a covariate. Changes from baseline (randomization)
to week 52 in AER, ACR, and BP were analyzed with a linear model
for ANCOVA.
If noninferiority was demonstrated superiority, comparisons were
performed using the Student t test for independent samples.24
Analyses were performed on 3 populations.27 The intention-to-
treat population, a per-protocol analysis, and finally, to assess
tolerability, a safety set analysis. Analyses on the intention-to-treat
population are presented unless otherwise stated. SAS software
(version 6.07) was used.
Results
Patient Enrollment and Baseline Characteristics
Potential patients (n621) were identified between March
1997 and January 2000. One hundred forty withdrew during
the 4-week run-in period, resulting in 481 (77%) randomly
assigned patients. Thus, 457 (95% of those randomly as-
signed) were considered as the intention-to-treat population;
375 patients (82% of the intention-to-treat population) ful-
filled the criteria for the per-protocol population (Figure 2).
There were no significant differences between the
intention-to-treat, per-protocol, and safety population in age,
gender, ethnicity, or duration of type 2 diabetes.
The characteristics of the patients are summarized in Table
1. There were no significant differences in baseline charac-
teristics between treatment groups. Baseline AER values
were nonsignificantly different in the perindopril/indapamide
group as compared with the enalapril group, as was the ACR.
All analysis was performed after adjustment on baseline
Figure 2. Flow chart of patient recruitment and inclusion in the
PREMIER study. *Total 140, as one patient could have more
than one exclusion criteria.
TABLE 1. Baseline Characteristics of Patients





Age, y range 58.2 (8.6) 30.0–78.0 59.6 (8.7) 36.0–75.0
Male, n (%) 132 (57) 148 (66)
BMI, kg/m2 30 (3) 30 (4)
Weight, kg 83 (12.4) 82 (13)
Height, cm 168 (9.4) 168 (9)
Ethnicity, n (%) White/black/Asian/other 218/8/2/5 (94/3/1/2) 198/12/2/12 (88/5/1/5)
HbA1c, % 7.2 (1.2) 7.3 (1.2)
AER, g/min* IQR 75.3 36.4–153.4 89.1 39.5–192.5
ACR, mg/mmol* IQR 7.9 3.4–18.1 9.2 4.5–17.5
SBP, mm Hg 158.0 (11.5) 158.8 (12.1)
DBP, mm Hg 93.3 (8.7) 93.3 (8.7)
Diabetes history
Duration, y 7.5 (6.6) 8.0 (6.9)
Requiring insulin, n (%) 68 (29) 83 (37)
Hypertension history
Duration, y 6.8 (7.9) 7.0 (7.3)
Previous treatment, n (%) 178 (76) 174 (78)
Diuretic, n (%) 31 (12) 31 (12)
RAS Inhibitor, n (%) 96 (41) 111 (50)
IQR indicates interquartile range. Data are expressed as mean (SD) except where otherwise
indicated.
*Geometric mean.
Mogensen et al Combination Therapy in Type 2 Diabetes 1065
 at SWETS SUBSCRIPTION SERVICE on May 7, 2009 hyper.ahajournals.orgDownloaded from 
value to ensure the comparison balance. There were fewer
men randomly assigned to perindopril/indapamide therapy,
but there were no gender differences in AER at baseline: 83
g/min men (64 to 108) compared with 87 g/min women
(64 to 118) (geometric mean, 95% CI, g/min). Similar
proportions in both treatment groups required dose adjust-
ments; 90 patients (39%) remained on 2 mg perindopril/0.625
mg indapamide, 71(30%) on 4 mg perindopril/1.25 mg
indapamide, 72 (31%) on 8 mg perindopril/2.5 mg indapam-
ide, as compared with 78 (35%) on 10 mg enalapril, 72 (32%)
on 20 mg enalapril, and 74 (33%) on 40 mg enalapril. Most
of the first dose adjustments occurred at week 12 (77%).
Effect on Blood Pressure and Urinary
Albumin Excretion
Blood Pressure
Both treatments reduced BP. Over the duration of the study,
BP (systolic/diastolic) was reduced by, on average,14.8/8.8
(15.8/9.3 SD) mm Hg in the group assigned to perindo-
pril/indapamide and 12.3/7.3 (15.5/9.0 SD) mm Hg in
the group assigned to enalapril. Perindopril/indapamide treat-
ment resulted in a statistically higher fall in BP (3.0 [95%
CI 5.6,  0.4] P0.012 for SBP; 1.5 [95% CI 3.0,
0.1] for DBP P0.019) (Table 2).
Mean BP (MBP) was lowered significantly more in the
group by perindopril/indapamide treatment than by enalapril
treatment (10.810.3 mm Hg perindopril/indapamide ver-
sus 9.010.1 mm Hg enalapril).
At the final visit, 159 of 233 (68%) patients in the
perindopril/indapamide group were responders versus 135 of
224 (60%) in the enalapril group.
Urinary Albumin Excretion
Both treatments significantly lowered AER, perindopril/inda-
pamide by a mean of 42% (95% CI 50% to 33%) and
enalapril by a mean of 27% (95% CI 37% to 16%).
Overall perindopril/indapamide remained more effective than
enalapril in reduction in albuminuria after adjustment for
baseline AER and country of origin (estimated treatment
effect, 24%; [95% CI 38% to 8%], P0.002, perindopril/
indapamide versus enalapril). AER was reduced by on
average 31.6 g/min by perindopril/indapamide and 24.4
g/min by enalapril (Table 2). Similar results were obtained
after additional adjustments for gender, body mass index, and
previous treatment of hypertension. Figure 3 illustrates that
changes in AER were maintained throughout the period of
follow-up.
The greater antiproteinuric effect in the perindopril/indap-
amide group remained after adjustment for MBP lowering,
with an estimated treatment effect: 22% [95% CI 36% to
6%, P0.005] and after adjustment for systolic BP of 22%
[95% CI 36% to 6%, P0.002]. Furthermore, for each
quartile of MBP change, the residual AER was consistently
lower in the perindopril/indapamide group (Figure 4). There
was a 29% reduction in AER in those treated with perindo-
pril/indapamide even in the quartile of patients with the
lowest fall in MBP (3.3 mm Hg), whereas in the group
treated with enalapril, in which there was no reduction in BP,
there was no reduction in AER.
The effect was present from low doses of perindopril/
indapamide, with a 30% reduction in AER in 90 of 233
patients who remained for the duration of the study on 2 mg
perindopril/0.625 mg indapamide first dose versus 25% for
the 78 of 244 who remained on 10 mg enalapril. Furthermore,
the greater effect on urinary albumin lowering remained after
adjustment for dose modifications (21% [95% CI 43% to
14%], P0.02).
Perindopril/indapamide treatment also lowered ACR by a
mean of 21% (95% CI 5% to 35%, P0.007) more than
enalapril. Similar results were obtained after additional ad-
justments for gender, body mass index, and previous treat-
ment of hypertension and different effect on BP. The results
were similar in the per-protocol analyses.
In the subgroup of patients with stricter definition of
microalbuminuria between 20 and 200 g/min at inclusion,
from a baseline of 62.0 and 62.2 g/min (geometric mean) in
the perindopril/indapamide and enalapril groups, respec-
tively, a reduction of 37% with perindopril/indapamide and
25% in AER with enalapril was observed.
Duration of Follow-up, Tolerability, and
Adherence to Treatment
The mean duration of follow up was 328 (99) days in those
assigned to perindopril/indapamide and 321 (106) in those
assigned to enalapril; 80% of those randomly assigned
completed the study. The main reasons for early withdrawal
were adverse events (19 of 244 perindopril/indapamide; 21 of
237 enalapril), nonmedical reasons (12 of 244 perindopril/
indapamide; 10 of 237 enalapril), major protocol deviations
(6 of 244 perindopril/indapamide; 4 of 237 enalapril), and
lack of efficacy (13 of 244 [5.2%] perindopril/indapamide; 25
of 237 [11%] enalapril, P0.03). One patient was lost to
follow-up. The global adherence to therapy was 97% (8) in
the perindopril/indapamide group and 99% (5) in the
enalapril group.
Tolerability was comparable between therapies. The pro-
portions of adverse events related to drug treatment were 47
events in 34 patients (13.9%) for perindopril/indapamide and
48 events in 35 patients (14.8%) for enalapril. The most
frequent were cough (perindopril/indapamide, 3.7%; enala-
pril, 2.1%) and dizziness (perindopril/indapamide, 1.2%;
enalapril, 2.1%). Analysis of serious cardiovascular adverse
events showed an incidence of 2.5% (6 of 244) in the
perindopril/indapamide group versus 6.3% (15 of 237) in the
enalapril group (relative risk2.65 [95% CI 1.03, 6.83],
log-rank test, P0.036) (Figure 5).
The biochemical changes are shown in Table 3. There was
a statistically significant mean change in HbA1c in both
groups [meanSD; perindopril/indapamide, 7.2% (1.4) to
7.7% (1.8); enalapril, 7.2% (1.4) to 7.4% (1.7)]. In
patients randomly assigned with higher levels of HbA1c
(8%), no significant change was observed (meanSD;
perindopril/indapamide, 0.0%1.8, n68, enalapril,
0.3%1.4, n77). The same proportion of patients in each
group required a change in their antidiabetic treatment during
the year of follow-up (perindopril/indapamide, 13%; enala-
pril, 11%), no patient became newly insulin-dependent. There
were small changes in creatinine clearance (Cockcroft for-
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mula), with no treatment difference (4.89.7 mL/min
perindopril/indapamide; 4.111.4 mL/min enalapril).
Eight patients (3.3%) had hyperkalemia (5.5 mmol/L) in
the perindopril/indapamide group versus 13 (5.5%) in the
enalapril group. Six patients (2.5%) had kalemia
3.4 mmol/L in the perindopril/indapamide group and 4
(1.7%) had kalemia 3.4 mmol/L in the enalapril group.
Discussion
This trial in patients with type 2 diabetes, hypertension, and
albuminuria demonstrates the benefits of first-line therapy
with a combination of a low dose of 2 mg perindopril, half the
conventional starting dose, and 0.625 mg indapamide, one-
quarter the conventional starting dose, in the reduction of
both BP and AER.
TABLE 2. Change in Albuminuria, Blood Pressure, and Response Rate





Albumin excretion rate, g/min
Baseline geometric mean IQR 75.3 36.4–153.4 89.1 39.5–192.5
Final geometric mean IQR 43.7 18.1–92.8 64.7 27.2–155.7
% AER reduction 95% CI 42% 50%–33% 27% 37%–16%
Estimated treatment effect Per/Ind/Ena 95% CI 0.76 0.62–0.92




Baseline geometric mean IQR 7.9 3.4–18.1 9.2 4.5–17.5
Final geometric mean IQR 4.8 1.9–9.9 6.7 2.8–15.2
% reduction albumin/creatinine ratio 95%CI 40% 48%–31% 27% 37%–16%
Estimated treatment effect Per/Ind /Ena 95%CI 0.79 0.65–0.95
Gain between Per/Ind and Ena 95%CI (1-estimated treatment effect) 0.21 0.05–0.35
P noninferiority* 0.001
P superiority† 0.007
Diastolic blood pressure, mm Hg
Baseline mean (SD) 93.3 (8.7) 93.3 (8.7)
Final 84.5 (9.2) 86.0 (9.8)
Change mean (SD) 8.8 (9.3) 7.3 (9.0)
Diff Per/Ind–Ena 95% CI 1.54 2.99–0.08
P equivalence‡ 0.265
P superiority§ 0.019
Systolic blood pressure, mm Hg
Baseline mean (SD) 158.0 (11.5) 158.8 (12.1)
Final 143.2 (16.5) 146.5 (17.0)
Change mean (SD) 14.8 (15.8) 12.3 (15.5)




Percentage of patients 68.2 60.3
*Noninferiority test: 1-tailed Student t test for independent samples (2.5%) after adjustment on W0 and country factor studied
on the log-transformed values of albuminuria with a limit of noninferiority of 0.30 and antilogged transformed to give clinical results
(1.35 antilogged limit).
†Superiority test: 1-tailed Student t test for independent samples (2.5%) after adjustment on W0 and country factor studied on
the log-transformed values of albuminuria with a superiority tested to 0 and antilogged transformed to give clinical results (superiority
tested to 1).
‡Equivalence test with limits of equivalence of 2–2 for DBP and 4–4 for SBP; two 1-tailed Student t test for independent
samples (2.5%) after adjustment on W0 and country factor.
§Superiority test to 0 mm Hg: 1-tailed Student t test for independent samples (2.5%) after adjustment on W0 and country factor.
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The combination therapy was superior in these respects to
monotherapy with enalapril an agent of proven benefit in terms of
renal and cardiovascular protection started at a conventional dose of
10 mg; 10 to 20 mg of enalapril and 4 to 8 mg perindopril are all
first-line therapy providing similar BP decrease.28
Given current BP targets, 	80% of patients with type 2
diabetes will have hypertension,29 whereas the estimated
prevalence of albuminuria in type 2 diabetes is 	30%.30
Thus, this study addresses a common clinical problem.
Increased urinary albumin excretion is associated with
worsened renal and cardiovascular outcomes, and BP-
lowering therapies that produce the largest reductions in
albuminuria give the greatest renal and cardiovascular pro-
tection.8,10 In the Micro–Hope substudy of the Heart Out-
comes Prevention Evaluation Study (HOPE),11 treatment
with an ACE inhibitor in 3577 patients with type 2 diabetes
lowered the risk of a combined end point of myocardial
infarction, stroke, or cardiovascular disease death by 25% and
total mortality rate by 24% as compared with placebo/
conventional antihypertensive drugs.
Cost-benefit analyses suggest that therapies that reduce
AER by 10% save money.31 Therefore, the mean estimated
treatment effect of a 24% greater reduction in AER in those
treated with perindopril/indapamide as compared with enala-
pril would have significant benefits in terms of cost savings.
The 42% reduction in AER demonstrated in this study with
perindopril/indapamide therapy is greater than that previously
reported in ACE inhibitor studies. Ravid et al32 described a
15% reduction in AER in 1 year with enalapril treatment in
type 2 diabetes, whereas Hallab et al33 described a 36%
reduction in AER using enalapril over a period of 1 year in
type 1 diabetes.
In a trial of irbesartan in 590 patients with type 2 diabetes
and microalbuminuria, there was a dose-dependent reduction
in AER of between 24% and 38% at 1 year, and this was
associated with up to a 70% risk reduction in the risk of
progression to overt albuminuria.10
In the Candesartan And Lisinopril Microalbuminuria
(CALM) study,34 which compared an ACE inhibitor with an
angiotensin II antagonist in patients with type 2 diabetes,
hypertension, and microalbuminuria, there was a 24% reduc-
tion in the ACR ratio with the use of a high dose of an
Figure 4. Change in AER (g/min by MBP quartile changes).
Figure 3. Decrease in percent AER at
each visit by treatment group.
Figure 5. Occurrence of serious cardiovascular adverse events
in PREMIER. Definition following ICD9-1975 revision (code 390-
448, 7981, instantaneous death).
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angiotensin II antagonist and a 39% reduction with the use of
the ACE inhibitor, which compares with a 40% reduction in
ACR in this study with perindopril/indapamide.
It is widely recognized that combination therapy is re-
quired to achieve current BP treatment targets. In the irbe-
sartan study in patients with type 2 diabetes and microalbu-
minuria, 	44% of the patients required additional
antihypertensive drugs.10
Perindopril/indapamide therapy was associated with
greater lowering of systolic and diastolic BP as compared
with enalapril, and this is usually associated with a greater fall
in AER.35 We do not have any data on salt intake; however,
the beneficial effect of the combination in BP lowering is
likely to be related at least in part to a diuretic-induced salt
loss, which potentiates the effect of RAS inhibition. The
BP-lowering effect of both perindopril/indapamide and ena-
lapril is undoubtedly crucial in lowering the AER. Neverthe-
less, the beneficial effects of the perindopril/indapamide
combination on AER persisted after adjustment for mean or
systolic BP reduction. Furthermore, there was an antiprotein-
uric effect at the lowest doses of perindopril and indapamide
and an 	30% reduction in AER even when the fall in MAP
was 3.3 mm Hg. This raises the suggestion of a renopro-
tective mechanism independent of systemic BP lowering with
this combination. Indapamide, in addition to its diuretic and
vasodilating effects, may act as a free radical scavenger,36,37
whereas RAS inhibitors including perindopril may also have
BP-independent renoprotective effects.38 The mechanism of
any BP-independent effect, however, has not been addressed
by this study.
In epidemiological studies, pulse pressure also has been
associated with microalbuminuria and may be a marker of
greater cardiovascular risk.39 We found a greater reduction in
AER with perindopril/indapamide as compared with enalapril
despite the fact there was no significant reduction in pulse
pressure, although we cannot in this study exclude that
lowering pulse pressure would be beneficial.
There has been some discussion recently as to whether
enalapril is more efficacious used twice daily. We cannot
exclude that differences occurred in nighttime BP and that
this may account in part for the benefits seen. However,
changes in nighttime BP are unlikely to be a major con-
founder of the results because the efficacy of the once-daily
enalapril regimen has been clearly demonstrated in diabetic
kidney disease.25,40 Second, a clinically and statistically
significant decrease in BP measured at trough was observed
in this study. As a reflection of the efficacy of both treatment
strategies in terms of BP lowering, approximately one third of
patients were adequately controlled on the lowest doses of
both therapies. Equal proportions in each group required dose
adjustments, with only approximately one third of patients
requiring the highest doses.
Treatment with the combination of perindopril/indapamide
was associated with some metabolic changes, notably a small
change in HbA1c predominantly seen in those with tight
glycemic control at inclusion, there being no deterioration in
those with a HbA1c 8% at baseline. There was no differ-
ence in the need to modify diabetic therapy between the
groups during the study, suggesting the effect was clinically
modest. Similarly, changes in the lipid profile were small.
These metabolic effects are commonly seen with diuretic
therapy and may be ameliorated by the combination with
ACE inhibitor therapy.41
The decrease in creatinine clearance seen in both groups is
in keeping with that seen with most antihypertensive therapy
and particularly with RAS inhibitors.
A lower incidence of serious cardiovascular events was
observed in the perindopril/indapamide group. It is difficult to
be certain of the significance of this finding because it was
not a designed end point of this study; therefore, it will need
to be confirmed in an appropriately designed study.
Perspectives
Recent guidelines indicate the importance of aggressive BP
lowering in patients with diabetes for both renal and cardio-
TABLE 3. Tolerability of Perindopril/Indapamide and Enalapril
Variable
Perindopril/Indapamide (n244) Enalapril (n237)
Baseline Final Value Change Baseline Final Value Change
Potassium, mmol/L 4.4 (0.4) 4.3 (0.4) 0.1(0.4)* 4.4 (0.4) 4.5 (0.4) 0.1(0.4)*
Sodium, mmol/L 139.6 (2.6) 138.7 (2.6) 0.8(3.1)* 140.0 (2.4) 139.4 (2.6) 0.7(2.4)*
Creatine Clearance, mL/min (Cockcroft formula) 95.1 (26.6) 91.1 (26.4) 4.8(9.7)* 90.4 (26.3) 86.1 (27.3) 4.1(11.4)*
Uric acid, mol/L 344.7 (76.9) 378.2 (89.9) 34.4(67.7)* 339.9 (81.1) 350.4 (88.5) 10.5(64.9)*
Glucose, mmol/L 9.2 (3.2) 9.5 (3.4) 0.4(3.7) 9.3 (3.3) 9.1 (3.1) 0.2(3.4)
HBA1c, % 7.2 (1.4) 7.7 (1.8) 0.6(1.6)* 7.2 (1.4) 7.4 (1.7) 0.2(1.4)*
Total cholesterol, mmol/L 5.3 (1.1) 5.5 (1.1) 0.1(0.9) 5.3 (1.1) 5.2 (1.0) 0.1(0.9)
HDL cholesterol, mmol/L 1.2 (0.3) 1.1 (0.3) 0.0(0.2)* 1.2 (0.3) 1.2 (0.3) 0.0(0.2)
LDL cholesterol, mmol/L 3.3 (0.9) 3.4 (0.9) 0.1(0.7) 3.3 (0.9) 3.3 (0.9) 0.0(0.7)
Triglycerides, mmol/L 2.0 (1.6) 2.4 (3.1) 0.4(2.1)* 2.0 (1.7) 1.8 (1.0) 0.2(1.7)
ALAT, IU/l 21.4 (11.7) 21.8 (12.5) 0.2(11.4) 20.9 (14.3) 19.8 (10.0) 0.7(9.8)
ASAT, IU/l 15.7 (6.9) 16.2 (9.1) 0.5(7.9) 15.8 (8.1) 15.0 (5.7) 0.7(5.8)
Data are mean (SD).
*P0.05.
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vascular prognosis.42 Achievement of these tight BP targets is
difficult, especially in those with albuminuria. The most
effective clinical strategies need to be determined. This study
demonstrates the efficacy of a low-dose combination of
perindopril/indapamide in both BP and AER reduction and
suggests that combination therapy should be offered early in
the treatment schedule of this important condition.
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